The design of targeted platinum (IV) prodrugs is a very promising approach to enhance the
low selectivity of platinum (II) drugs towards cancerous tissue in order to reduce the impact …

Oxaliplatin is a very potent platinum (II) drug which is frequently used in poly-chemotherapy
schemes against advanced colorectal cancer. However, its benefit is limited by severe …

Chemotherapy with platinum complexes is essential for clinical anticancer therapy.
However, due to side effects and drug resistance, further drug improvement is urgently …

Platinum (IV) prodrugs are a promising class of anticancer agents designed to overcome the
limitations of conventional platinum (II) therapeutics. In this work, we present oxaliplatin (IV) …

Classical platinum (II) anticancer agents are widely-used chemotherapeutic drugs in the
clinic against a range of cancers. However, severe systemic toxicity and drug resistance …

Four platinum (II) complexes (13− 16) were synthesized by reacting either [Pt trans-
DACH](NO3) 2 with a 6-maleimidocaproic acid, a 15-maleimido-4, 7, 10, 13 …

Platinum anticancer drugs are particularly in need of controlled drug delivery because of
their severe side effects. Platinum (IV) agents are designed as prodrugs to reduce the side …

The efficacy of traditional chemotherapy often suffers from rapid clearance and off-target
toxicity. Drug delivery systems and controlled release are applied to improve the therapeutic …

A novel and highly efficient dual‐targeting platform was designed to ensure targeted in vivo
delivery of dual‐action PtIV prodrugs. The dual targeting was established by liposomal …

We have developed a novel albumin-binding prodrug of doxorubicin that incorporates p-
aminobenzyloxycarbonyl (PABC) as a 1, 6 self-immolative spacer in addition to the …